Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction
Open Access
- 30 November 2005
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 41 (17), 2682-2689
- https://doi.org/10.1016/j.ejca.2005.02.007
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- A New clinical score for disease activity in Langerhans cell histiocytosisPediatric Blood & Cancer, 2004
- Efficacy of continuous infusion 2‐CDA (cladribine) in pediatric patients with Langerhans cell histiocytosisPediatric Blood & Cancer, 2004
- Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study GroupBone Marrow Transplantation, 2003
- 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell HistiocytosisMayo Clinic Proceedings, 2003
- Langerhans Cell Histiocytosis in a Patient with Systemic Lupus Erythematosus: A Clonal Disease Responding to Treatment with Cladribine, and CyclophosphamideLeukemia & Lymphoma, 2002
- Successful Treatment of Langerhans'-Cell Histiocytosis with EtanerceptThe New England Journal of Medicine, 2001
- Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 StudiesKlinische Padiatrie, 2000
- Cyclosporine therapy for refractory langerhans cell histiocytosisMedical and Pediatric Oncology, 1995
- 2-Chlorodeoxyadenosine to Treat Refractory Histiocytosis XThe New England Journal of Medicine, 1993
- TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS WITH ALPHA-INTERFERONThe Lancet, 1987